Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is among the best stocks with the highest upside potential. Guggenheim assumed coverage on Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) with a “Buy” rating and a price target of $8.00, implying a surge of 146.5% from the current price. The analysts have high expectations for the company’s silevertinib Phase 2 data due in the second half of 2025. Guggenheim believes silevertinib’s preclinical profile, which is designed for broad-spectrum mutation selectivity ...